|Day's Range||53.30 - 57.58|
|52 Week Range||37.05 - 75.36|
|PE Ratio (TTM)||-44.53|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Seattle Genetics, FibroGen and Sangamo were among the biotech stock movers in premarket trading on June 26.
These stocks dropped despite a mostly flat market. Find out why.
It could have been worse though — you could have owned Stratasys, Ltd. (NASDAQ:SSYS), Arconic Inc (NYSE:ARNC) and Seattle Genetics, Inc. (NASDAQ:SGEN). Seattle Genetics shareholders got the new trading week started on the wrong foot, with SGEN sliding 8.4% following reports that one of its cancer drug trials didn’t quite live up to expectations. The drug, called Adcetris, was being co-developed by Japanese biopharma outfit Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) as a therapy for certain forms of blood cancer.